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ABSTRACT 
Tumor-induced myeloid derived suppressive cells (MDSC) have been reported to inhibit T cell 
responses. In our study MDSC isolated from tumor bearing mice showed potent inhibition of 
 T-cell proliferation. However, surprisingly we observed that freshly isolated MDSC from the bone 
marrow of tumor bearing mice do not constitutively express arginase-1 until after exposure to T-
cell proliferation. The aim of this study is to determine the mechanism by which arginase-1 is 
induced in MDSC following exposure to a proliferative T cell environment. We showed that 
treatment of MDSC with culture supernatant isolated from T cells activated with CD3/CD28 
antibodies successfully induced arginase-1 expression and this process is independent of IL-10 
and IFNγ. This suggested that arginase-1 induction in MDSC can occur independently of cell-cell 
contact. Interestingly IL-2, ConA or PMA activated T-cell supernatant as well as supernatant from 
multiple cancer cell lines failed to induce arginase-1 in MDSC. We also showed that M-MDSC 
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expressed higher levels of arginase-1 than G-MDSC after co-culture with CD3/CD28 activated T 
cells as well as its supernatant. In addition, other bone marrow cells have shown the potential to 
express arginase-1 following exposure to the same conditions. For example, we observed that 
healthy Ly6C+ monocytes but not mature granulocytes successfully expressed arginase-1.These 
data demonstrated that T cells activated through stimulation of TCR but not other means of 
activation induced arginase-1 enzyme expression. 
 
 
 
 
INDEX WORDS: Myeloid derived suppressor cells, CD3, T cells, Arginase-1. 
  
vi 
 
Induction of arginase-1 in MDSC requires exposure to CD3/CD28 activated T cells 
 
 
 
 
by 
 
 
 
 
AHMED ABDELAAL 
 
 
 
 
 
 
A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of 
MASTER OF SCIENCE 
in the College of Arts and Sciences 
Georgia State University 
2016 
vii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
AHMED MANSOUR ABDELBAKY ABDELAAL 
2017  
viii 
 
Induction of arginase-1 in MDSC requires exposure to CD3/CD28 activated T cells 
 
 
by 
 
 
AHMED ABDELAAL 
 
 
 
Committee Chair:  Yuan Liu 
 
Committee:      
       1- William Walthall 
       2- Deborah Baro 
 
Electronic Version Approved: 
 
Office of Graduate Studies 
College of Arts and Sciences 
Georgia State University 
May 2017   
ix 
 
 
DEDICATION 
This work is dedicated to my family. Mom, Dad, Eng. Mohammed, Drs. Islam and Eman 
who have always been my strengths. I appreciate all of your patience and encouragement. 
 
  
ACKNOWLEDGEMENTS 
 In the name of Allah, Most Gracious, Most Merciful .Praise be to God for his kindness 
and thanks to him for the guidance. 
 
I would like to express my deepest gratitude to my mentor Dr. Yuan Liu. I would like to 
take the opportunity to thank her for her support, guidance and patience. Under your guidance, I 
have learnt how to trust in my abilities to achieve my goals. Thank you for constantly inspiring 
me to strive for excellence.  
 
I would also like to thank my committee members, Drs. William Walthall and Deborah 
Baro for their valuable guidance during my graduate career. Thank you for your constructive 
feedback during the project. Thank you both for always supporting me, and helping me achieve 
my goals, it is truly appreciated. 
 
I would also like to express my gratitude to the ministry of higher education in Egypt and 
USAID organization for providing financial support for my study for the past two years. 
 
I would like also to extend my gratitude to the Department of biology at Georgia State 
University for your scientific support.  
 
Thank you to my lab members for helping me through all of my experiments. I sincerely 
appreciate all of your help. 
 
  
I would like to sincerely thank my professors in Egypt for all of their scientific and 
emotional support. I appreciate all of your guidance during my undergraduate studies. 
 
I would like to thank all of my friends Dr.Ahmed Abdelsattar, Dr.Ahmed Abdelbaki, 
Dr.Moamen Almaz, Dr.Attia Mohammed, and Eng.M. El-sayed, Dr.M.Eldahshan, Mr. E.Elwan, 
Mr.M.Abdelhaleem and Mr. A.Abdalla for all of their support in their own special ways.
iii 
 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .............................................................................................. i 
LIST OF FIGURES .......................................................................................................... v 
LIST OF ABBREVIATIONS ......................................................................................... vi 
1 INTRODUCTION ...................................................................................................... 1 
1.1.1 Myeloid Derived Suppressor cells................................................................... 1 
1.1.2 History of MDSC ............................................................................................. 1 
1.1.3 MDSC origin ................................................................................................... 1 
1.1.4 MDSC phenotypic markers ............................................................................. 2 
1.1.5 Characteristics of M-MDSC ........................................................................... 2 
1.1.6 Characteristics of G-MDSC ............................................................................ 3 
1.1.7 MDSC in different disease conditions ............................................................ 3 
1.1.8 MDSC expansion and activation mechanisms .............................................. 5 
1.1.9 Mechanisms of MDSC suppressive activity. .................................................. 6 
1.2 Overview on T cells ........................................................................................... 11 
1.2.1   T cell development and maturation ................................................................ 11 
1.2.2       T cell activation .......................................................................................... 12 
2 MATERIALS and METHODS ............................................................................... 14 
2.1 Mouse tumor models ......................................................................................... 14 
2.2 Isolation of bone marrow .................................................................................. 14 
iv 
 
2.3 Separation of leukocytes from bone marrow .................................................. 14 
2.4 Isolation of splenocytes and T cells .................................................................. 15 
2.5 T-cell proliferation assay .................................................................................. 16 
2.6 Western blot (WB) analysis of arginase .......................................................... 17 
2.7 Flow cytometry analysis.................................................................................... 17 
2.8 Measurement of the cytokines ........................................................................... 17 
3 Results ........................................................................................................................ 19 
3.1 Bone marrow-derived MDSC from tumor bearing mice suppress T cell 
proliferation… ......................................................................................................................... 19 
3.2 Tumor bone marrow MDSC express arginase-1 upon exposure to TCR-
activated T cells ....................................................................................................................... 22 
3.3 Arginase-1 expression by BM derived MDSC is independent of direct 
contact with T cells. ................................................................................................................. 25 
3.4 Arginase-1 induction in BM derived MDSC by activated T cells requires 
ligation of TCR co-receptor (CD3). ....................................................................................... 26 
3.5 Healthy Ly6Chigh monocytes but not Ly6G+ granulocytes express arginase-1 
only after -the exposure to CD3/CD28 activated T cells. ..................................................... 29 
4 Discussion .................................................................................................................. 31 
REFERENCES ................................................................................................................ 33 
 
 
v 
 
LIST OF FIGURES 
Figure 1-1MDSC origin. ............................................................................................................... 4 
Figure 1-2MDSC mechanisms of suppression. ......................................................................... 10 
Figure 2-1 T-cell proliferation assay………………………………………………………......16 
Figure 3-1 Bone marrow-derived MDSC from tumor bearing mice suppress T cell 
proliferation. ................................................................................................................................ 21 
Figure 3-2 Bone marrow-derived MDSC express no arginase but until after exposure to 
activated T cells. .......................................................................................................................... 24 
Figure 3-3 Arginase-1 expression by BM derived MDSC is independent of direct contact 
with T cells. .................................................................................................................................. 27 
Figure 3-4 Arginase-1 induction in BM derived MDSC by activated T cells requires ligation 
of TCR co-receptor (CD3). ......................................................................................................... 28 
Figure 3-5 Healthy Ly6Chigh monocytes but not Ly6G+ granulocytes express arginase-1 only 
after the exposure to CD3/CD28 activated T cells. .................................................................. 30 
  
 
 
 
 
 
 
 
 
vi 
 
LIST OF ABBREVIATIONS 
BM-Bone Marrow 
MDSC-Myeloid-derived suppressor cells 
IMC-Immature myeloid cells 
IL-Interleukin 
VEGF-Vascular endothelial growth factor 
MΦ-Macrophage 
IFN-γ-Interferon gamma 
ROS-Reactive oxygen species 
RNS-Reactive nitrogen species 
TCR-T cell receptor 
MHC-Major histocompatibility complex 
NF-κB-Nuclear factor kappa B 
HSC-Hematopoietic stem cell 
JAK-Janus kinase 
STAT-Signal transducer and activator of transcription 
Treg-Regulatory T cell 
GM-CSF-Granulocyte/Macrophage colony-stimulating factor 
G-CSF-Granulocyte colony-stimulating factor 
CMP-Common myeloid progenitor 
iNOS-Nitric oxide synthase 
Arg-Arginase 
CAT-2B Cationic amino acid transporter 2B  
vii 
 
G-MDSC-Granulocytic MDSC 
M-MDSC-Monocytic MDSC 
NO-Nitric oxide 
ELISA-Enzyme-linked immunosorbent assay 
HRP-Horseradish peroxidase 
RBC-Red blood cell 
FACS-Fluorescence activate cell sorting 
CFSE-Carboxyfluorescein succinimidyl ester 
CD-Cluster of differentiation 
ConA - Concanavalin A 
iNOS- Inducible nitric oxide synthase 
COX2-Cyclooxygenase-2 
SCF-Stem cell factor  
CXCR- chemokine receptor 
PD/PDL-Programmed death receptor/ligand 
CTLA-Cytotoxic T-lymphocyte antigen 
HVEM- herpes virus entry mediator  
PKC –Protein kinase C
1 
 
1 INTRODUCTION  
 
1.1.1 Myeloid Derived Suppressor cells  
Myeloid derived suppressor cells are a heterogeneous population of immature myeloid cells 
that have been associated with a potent suppression of the immune system including both 
innate and adaptive immunity[1, 2]. 
1.1.2  History of MDSC 
Myeloid derived suppressor cells (MDSC) were first observed associated with tumor evasion  in 
the early 1900s[3]. This observation was explained as an extreme deprivation of neutrophils 
(neutropenia) and an extramedullary hematopoiesis, which was also associated with abnormal 
myeloid cells differentiation [3] . Null cells , Veto or natural suppressor cells were used to describe 
this population of cells as they do not have any distinct cell surface markers that distinguish them 
from other cells as T cells,  B cells, NK cells or  macrophages [3]. A few years later, these cells 
were reported to inhibit T- cell proliferation and activity [4].In 2007, the name “ Myeloid derived 
suppressor cells” was formally used to describe this population of suppressor cells[5].Recently, 
many  reports describe the biology and the significance of this population of cells in different 
disease conditions[6]. 
1.1.3 MDSC origin 
Different factors including granulocyte macrophage colony-stimulating factor (GM-CSF), 
macrophage colony-stimulating factor (M-CSF), stem-cell factor (SCF) control myelopoiesis. 
During normal myelopoiesis, Hematopoietic stem cells (HSCs) form common myeloid progenitor 
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(CMP) cells which differentiate into immature myeloid cells (IMCs)[2] .Lastly IMCs differentiate 
into macrophages, granulocytes and dendritic cells. Under different disease conditions such as 
cancer, trauma and inflammation, immature myeloid cells (IMCs) lose their ability to form mature 
cells and instead give rise to myeloid derived suppressor cells (MDSC)[2] (Fig. 1-1). 
1.1.4 MDSC phenotypic markers 
One of the most challenging issues in the field of MDSC, is the lack of specific surface marker to 
distinguish suppressive granulocytes from non-suppressive granulocytes [7]. In mice, CD11b and 
Gr-1 protein, which include two isoforms (LY6C and LY6G) still the most useful markers to 
describe MDSC. However, these markers are not MDSC specific [7] . MDSC involve two 
populations of myeloid leukocytes:  Granulocytic MDSC (G-MDSC) , which can be described as 
CD11b+, Ly6Clow, Ly6G+cells, and monocytic MDSC (M-MDSC), which can be described as CD11b+, 
Ly6Chigh, Ly6G-[8]. Both M-MDSC and G-MDSC have been reported to inhibit T cell responses 
including T-cell proliferation and functions [2]. In addition to the difference in phenotype, M-
MDSC and G-MDSC are also different in the mechanisms of their immunosuppressive function[9].  
1.1.5 Characteristics of M-MDSC 
There are 2 subpopulations of MDSCs, the monocytic MDSC, and the granulocytic MDSC.As 
previously mentioned M-MDSC and G-MDSC have different surface markers as well as different 
immunosuppressive mechanisms. Monocytic MDSC immunosuppressive function is believed to 
be  generated primarily by the upregulation of both arginase-1(Arg-1) enzyme and inducible nitric 
oxide synthase (iNOS) as well as by suppressive cytokines[10].Arginase-1 enzyme acts by 
depleting L-arginine from the environment by degrading it into L-ornithine and urea. Inducible 
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nitric oxide synthase (iNOS) breaks down L-arginine into nitric oxide (NO) which induces T cell 
apoptosis[10]. 
 
1.1.6 Characteristics of G-MDSC 
Granulocytic-MDSC, which is characterized by high expression of the neutrophilic marker Ly6G+, 
shares some common characters with the mature neutrophils including the formation of 
intracellular granules and the expression of NADPH oxidase, the enzyme responsible for the 
production of reactive oxygen species (ROS)[2]. ROS works in combination with NO to form 
peroxynitrite radicals, that inhibit cytotoxic T cell responses through nitration of the T-cell 
receptor making T-cells unresponsive to antigen stimulation[10, 11].In addition, it has been 
reported that G-MDSC produces TGF-β, which enhances tumor invasion, metastasis and 
suppresses the immune response[10, 12]. 
 
1.1.7 MDSC in different disease conditions 
As previously discussed, MDSCs were first discovered in patients with cancer or in tumor-bearing 
mice[2]. It also has been reported that there is a marked expansion of myeloid derived suppressor 
cells in patients with different cancers [2, 13]. However, MDSCs are also found in other diseases 
such as trauma, acute and chronic inflammation, transplantation and sepsis[2]. Expansion of 
MDSCs is also associated with different autoimmune diseases such as inflammatory bowel 
disease (IBD), which suggests that MDSCs are observed under different pathological conditions[2, 
14]. 
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Figure 1-1MDSC origin. 
Under healthy conditions, hematopoietic stem cells (HS) give rise to common myeloid progenitor 
cells (CMP), then into immature myeloid cells (IMC) that finally differentiate into mature 
granulocytes, macrophages or dendritic cells. In the case of tumor, trauma or infections, IMC are 
forced by the diseases environment to stay in the immature state and become myeloid derived 
suppressor cells (MDSC). 
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1.1.8 MDSC expansion and activation mechanisms 
Many studies have shown that many factors are able to regulate MDSCs expansion or activation. 
An interesting review by Dmitry I. Gabrilovich et al. showed that these factors can be classified 
into two main groups: 1) those that control MDSCs expansion, and 2) those that control MDSCs 
activation. The first group are produced mainly by tumor cells, and work by preventing the 
formation of mature myeloid cells. The second are produced by tumor stromal and activated T 
cells [2]. 
1.1.8.1 Factors that control MDSC expansion  
Factors reported to control MDSC expansion include vascular endothelial growth factor (VEGF)[2, 
15], cyclooxygenase-2 (COX2)[2, 16], granulocyte/macrophage colony-stimulating factor GM-
CSF[2, 17] and IL-6 [2, 18] , stem-cell factor (SCF)[19] and prostaglandins[2].Interestingly, most of 
these factors activate the JAK-STAT3 signaling pathway.Stat-3 phosphorylation is also 
upregulated in MDSCs from tumor bearing mice [2, 20]. It has been reported that selective STAT3 
inhibitors successfully enhance T- cell responses by reducing MDSCs expansion[2, 20]. A recent 
study from our laboratory showed that, CXCR2-expressing granulocytic MDSC (G-MDSC) but not 
monocytic MDSC (M-MDSC) isolated from tumor bearing mice expand during tumor progression. 
This suggests that G-MDSC are the most important immunosuppressive cells regulated during 
tumor growth. 
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1.1.8.2 Factors that control MDSC activation  
In addition to the factors that promote MDSCs expansion, MDSCs require factors to induce their 
activation. These factors include IL-4, IL-13, Transforming growth factor-β (TGFβ) and 
IFNγ[2].Treatment of freshly isolated MDSCs from the spleen of tumor bearing mice or cloned 
MDSCs cell lines with IL-4 upregulate arginase-1 expression[21].  
It has been demonstrated that IL-13 and IL-4 treatment upregulate arginase-1 expression in bone 
marrow derived macrophages (BMDM)[22].Importantly, IL-13 and IL-4 binds to (IL-4Rα) and this 
pathway involves STAT-6 activation[2]. However, in a different study using a breast tumor model 
, IL-4Rα deficient mice contain MDSCs after surgery[23].  
Another study has attributed the upregulation of Arg-1 and iNOS in MDSCs isolated from 
spleen of tumor bearing mice to STAT-1 signaling pathway which is mediated by IFNγ[24]. 
1.1.9 Mechanisms of MDSC suppressive activity. 
MDSCs use different mechanisms to suppress both adaptive and innate immunity components 
including depletion of L-arginine, ROS and RNS production or induction of Treg. Many studies 
have shown that MDSCs suppressive function require direct contact with T cells[2]. 
1.1.9.1 Depletion of L-arginine 
L-arginine plays an important role in T-cell proliferation, activation, metabolism and functions 
[25, 26]. L-arginine can act as a substrate for many enzymes including arginase- I, arginase- II, and 
nitric oxide synthase [25].  
It is now well established that arginase-1 activity promotes tumor growth and escape from 
immune-surveillance through depletion of L-arginine [27]. Arginase-1 activity has been detected 
7 
 
in the tumor microenvironment of skin, breast and prostate cancer and is considered as a marker 
of tumor progression in patients with different tumor models[27].  
In a study using 3LL murine lung carcinoma model, it has been reported that mature myeloid cells 
isolated from the tumor microenvironment; successfully inhibit T-cell proliferation and 
expression of signaling molecules in an arginase-1 dependent manner[28]. However, arginase-1 
expression and suppressive activity is not restricted to mature myeloid cells.  
 Using arginase-1 and iNOS, MDSCs  break down L-arginine into L-ornithine and urea [2, 
25].Arginase-1 expression in MDSC is associated with inhibition of T-cell responses including 
down regulation of CD3ζ expression [2, 29]while NO inhibits T cell responses through the 
induction of T-cell apoptosis or inhibition of MHC class II expression [2, 30, 31]. Interestingly, 
many reports showed that inhibition of arginase-1 was able to rescue T-cell proliferation [32-34] 
[33]and is also to inhibit tumor growth which suggests that maintaining L-arginine levels in T-cell 
environment is very important in preventing the immunosuppression by MDSCs[32] . 
Importantly, Murine MDSCs deplete the extracellular L-arginine levels by increasing the uptake 
of L-arginine through the cationic amino acid transporter 2B (CAT-2B) while human MDSCs do 
not uptake L-arginine but release arginase-1 enzyme within granules into the microenvironment. 
This induces L-arginine depletion which inhibits T-cell proliferation [28, 35, 36]. 
1.1.9.2 ROS 
In the tumor microenvironment, reactive oxygen species (ROS) are produced by MDSCs, 
neutrophils, eosinophils, regulatory T-cells, macrophages and tumor cells. ROS are associated 
with the inhibition of T-cell responses and the enhancement of tumor growth [37, 38]. One of 
the main characteristics of MDSCs in cancer patients and tumor-bearing mice is elevated ROS[2, 
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39, 40].Inhibition of ROS production by MDSCs in these cancer patients and tumor-bearing mice 
completely rescues T-cell functions[2, 39, 40].It has been shown that, integrins on the MDSCs 
surface play a role in ROS production since blocking integrins (CD11b, CD18, and CD29) by specific 
antibodies completely abolishes the suppressive function of MDSCs [2, 40]. 
ROS inhibit T-cell responses through different mechanisms such as blocking the interaction 
between T-cell receptor (TCR) and the major histocompatibility complex (MHC)[2, 11, 41] , 
inhibiting the differentiation of MDSCs into macrophages so MDSCs will stay in the immature 
state [2, 42] or depleting cystine and cysteine which causes inhibition of  T-cell activation and 
function[37, 43].In addition, it has been reported that MDSCs can induce T-cell apoptosis via ROS 
dependent mechanisms[37, 44, 45].However, low levels of ROS can induce T-cell activation and 
proliferation[37, 46, 47]. 
1.1.9.3 Reactive nitrogen species (RNS) 
RNS are considered as an important immune-suppressive instrument used by MDSCs to suppress 
T cell responses. For example peroxynitrite (ONOO-) induces cysteine, tryptophan, methionine 
and tyrosine nitration and nitrosylation[2, 48]. It has been shown that peroxynitrite makes T-cell 
unresponsive to different stimuli through the nitration of TCR and CD8 molecules[11].Another 
study showed that peroxynitrite induces T-cell apoptosis through impairment of tyrosine 
phosphorylation[49]. 
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1.1.9.4 Other mechanisms 
In addition to previous mechanisms by which MDSCs inhibit T-cell responses, several studies 
demonstrate that MDSCs can also induce regulatory T-cell  (Treg ) development which is shown 
to be independent of NO but  requires the presence of TGF-β and IL-10 [2, 50] .Furthermore, 
arginase-1 is reported to enhance Treg expansion in lymphoma bearing mice[51]. 
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Figure 1-2MDSC mechanisms of suppression. 
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1.2  Overview on T cells  
1.2.1   T cell development and maturation 
T cell development takes place in the thymus where the bone marrow hematopoietic stem cells 
(HSCs) generate lymphoid progenitor cells which give rise to thymocytes[52]. Two characteristics 
are required for the bone marrow cells to generate T cell lineage progenitors. First, the ability to 
move to the thymus[52, 53]. Second, they must have a potential to generate T cells in  the 
thymus[52, 54].  Based on the expression of either CD4 or CD8 surface marker, T cells undergo 
different selection steps in the thymus[55].The earliest thymocytes are double negative which 
mean that no expression of either CD4 or CD8 surface markers (CD4– CD8–)[55]. These double 
negative cells can be further classified based on the expression of CD117, CD44 or CD25[55].Then 
they become double positive (CD4+CD8+) through their development and end as single positive 
thymocytes (CD4+CD8− or CD4−CD8+)  which leave to the peripheral organs [55]. 
T cell fate is determined by the strength of the interaction between the major histocompatibility 
complex (MHC) and the T cell receptor[56]. Double positive thymocytes that express T cell 
receptor and have intermediate interaction with the major histocompatibility complex of the 
cortical epithelial cells, undergo positive selection process to form a mature single positive naïve 
T cell. If the T cell receptor of the double positive thymocytes failed to interact with the major 
histocompatibility complex, the thymocytes will die by neglect. The thymocytes will be deleted 
by negative selection if the interaction is too strong. Each day, about 50 million double positive 
thymocytes (CD4+CD8+) are generated in the mouse thymus[57].More than 90 % of these cells 
have T cell receptor that lack positive selection ability thus these cells undergo death by neglect 
as they failed to interact with the major histocompatibility complex[56]. 
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1.2.2       T cell activation 
T cell activation requires  two signals. The first signal is driven after the interaction between the 
T cell receptor (TCR) and the major histocompatibility complex (MHC) on the surface of antigen 
presenting cell. The second signal is a costimulatory signal between co-stimulatory molecules on 
the surface of T cells and costimulatory receptor on the surface of the antigen presenting cell[58]. 
For example, the costimulatory molecule CD28 binds to CD80 or CD86 receptors on the surface 
of the antigen presenting cell[58]. In addition to the costimulatory molecules , there are co-
inhibitory molecules as CTLA-4 and PD-1 which lead to T cell exhaustion after the binding with 
CD80 , CD86 or PDL-1 receptors[58]. 
The TCR consists of α and β-chain that is linked with CD3 subunits[59]. The binding between TCR 
and (MHC) complex lead to initiation of downstream signaling pathways that cause T cell 
proliferation, differentiation and cytokines secretion[58, 59]. Although the first signal through 
TCR is enough for T cell activation, the costimulatory signals are very important to sustain the 
proliferation of naïve T cells through the activation of NF-κB signaling pathway[59, 60].The CD28 
role in enhancing T cell proliferation was confirmed using CD28 deficient T cells [61].In addition 
to the antigen (Ag)-dependent activation of T cells through the binding of TCR to the MHC 
complex ,T cells activation can occur independently of the binding between TCR and MHC 
complex in an Ag-independent way. Different substances as anti-CD3 monoclonal antibody, PMA 
plus ionomycin or concanavalinA (ConA) are known to activate T cells[62]. Anti-CD3 monoclonal 
antibody activates T cells by stimulating the signaling down stream of TCR, while PMA plus 
Ionomycin induce protein kinase C (PKC) activation [62].ConcanavalinA (ConA) binds to the TCR 
and other cell surface glycoproteins[62, 63] and its role in T cell activation is shown to be 
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regulated by herpes virus entry mediator (HVEM)[62], which promotes T cell activation , 
proliferation and cytokine production by  co-operating with CD3/TCR signaling[64]. 
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2 MATERIALS and METHODS 
2.1 Mouse tumor models  
C57BL/6J mice (6-8 week, 20-22 g, Jackson Laboratory) were subcutaneously (s.c.) engrafted 
(allograft) with B16 melanoma with 2 × 105 B16 (B16F10) cells injected in 300 µl sterile PBS. B16 
cells (ATCC) were cultured in DMEM supplemented with 10% FBS. After engraftment, tumor 
developed in 2-3 weeks. 
2.2  Isolation of bone marrow  
The femur and tibia of euthanized mice were removed from each mouse and the surrounding 
tissue was removed. The bone ends were removed from the diaphysis with scissors surgically, 
so the bone marrow rich medullary cavity was exposed. A syringe was filled with 4mls ice-cold 
PBS. The PBS washed out all the bone marrow into a 15ml BD Falcon conical collection tube as 
it pass through the medullary cavity. The cell suspension was centrifuged at 1000RPM, 4°C for 
10 minutes. The pellets were resuspended in sodium bicarbonate, ammonium chloride, EDTA 
lysis buffer to lyse any red blood cells from the bone marrow. After lysis of the RBCs, the cells 
were washed in PBS and centrifuged again.     
2.3 Separation of leukocytes from bone marrow 
 Bone marrow leukocytes were collected by flushing the femur and tibia of previously 
euthanized mice using iced-cold PBS followed by lysis of RBCs using RBCs lysis buffer. 
Enrichment and separation of the myeloid cells from the collected leukocytes were performed 
using percoll dentistry gradient as previously described. In brief, Percoll gradient was prepared 
using Percoll (Sigma) by mixing of 9 mls of Percoll with 1 ml of 10 × HBSS followed by filtration 
and  dilution by 1 × HBSS to prepare different Percoll solutions with different densities: 70% 
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(1.097 g/mL)g/mL), 60% (1.083 g/mL), 50% (1.071 g/mL), 40% (1.058 g/mL) . Five-layer 
discontinuous density gradients were prepared by adding one layer (2 ml/layer) upon one 
another starting with the layer with the highest density at the bottom in a 15 ml tube using a 
syringe fitted with a 22G needle. About 7 x107 bone marrow leukocytes were suspended in 1 
mL HBSS and then  placed on top of the gradients using a syringe with 22 G needle, followed 
by centrifugation at 600 g x g for 40 min in a swinging bucket rotor. After the centrifugation, 
the cells were separated and formed bands at the interface between each 2 layers. Cells in band 
III were collected, washed and analyzed by FACS. PE-conjugated anti-Ly6G antibody and PE-
conjugated magnetic microbeads were used to isolate granulocytes (LY6G+) by positive 
selection, while the rest without binding to the beads contained about 90 % of 
Ly6Chigh monocytic leukocytes. 
2.4 Isolation of splenocytes and T cells 
To isolate cells from tumor tissues or the spleen, tumor tissues or spleen were grounded and were 
digested with collagenase D (400 U/ml) at 37οC (45 min) in HBSS with agitation following by 
filtration through nylon mesh with the pore size of 70 µm diameter and collection in ice-cold 
RPMI 1640 Spleen tissues were grinded in HBSS. The pellets were resuspended in red blood 
cell lysis buffer to lyse any red blood cells from the spleen. After lysis of the RBCs, the cells were 
washed in HBSS and centrifuged again followed by collection in ice-cold RPMI 1640 with 10% 
FBS. To purify CD4+ and CD8+ T cells, PE-conjugated anti-CD4+ antibody and PE-conjugated 
anti-CD8+ antibody, PE-conjugated magnetic microbeads (Miltenyi Biotec.) were used for 
positive selection and the finally purified CD4+ and CD8+ T-cells were confirmed to have a 
purity of > 95% by using of fluorescence microscopy. 
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2.5 T-cell proliferation assay     
 Carboxyfluorescein diacetate succinimidyl ester (CFSE) was used to label splenocytes (6 × 105) 
following their isolation from mice or purified T cells (6 × 105) after further purification as 
mentioned above, followed by washing. Labeled splenocytes (6 × 105) or purified T cells were 
seeded in 96-well pre-coated with anti-CD3 (1 µg/ml, clone 145-2C11, Biolegend). RPMI1640 
with 10% FBS and soluble anti-CD28 (0.5 µg/ml, clone 37.51, Biolegend) was added followed by 
the incubation of cells at 37°C, 5% CO2 for 4 days. For the co-culture experiment, MDSC isolated 
from the bone marrow were added to splenocytes at the ratio of 1:3 or to purified T cells at the 
ratio of 1:1.After 4 days, Cells were collected and labelled with fluorescent anti-CD8 and CD4 
antibodies (Biolegend) and analyzed by FACS to evaluate T-cell proliferation. 
 
Figure 2 1T cell proliferation assay. 
Splenocytes labelled with CFSE, activated by CD3 and CD28 antibodies, after each cell       
division, the intracellular CFSE will become more diluted. 
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2.6 Western blot (WB) analysis of arginase 
 Freshly isolated bone marrow derived M-MDSC or G-MDSC that were separated by 
Percoll, BM Ly6G+ granulocytes and Ly6C+ monocytes after co-culture with splenocytes or 
treated with CD3/CD28 activated T cell supernatant were lysed in a buffer containing 100 
mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, protease inhibitors (Sigma, Product 
Code: P8340) and 3 mM PMSF following by centrifugation at (10,000 rpm, 10 min), cell 
lysates  were separated by 10 %  SDS-PAGE after adding of 5x loading buffer , followed by 
transferring onto nitrocellulose for 2 hrs , constant  current at 0.3 A then  blocking with 
5% non-fat milk. The membrane was incubated with anti-arginase 1 (mAb H-52, Santa 
Cruz Biotechology), secondary antibody and ECL. Β-actin in cell lysates was detected by 
using anti- β-actin (Santa Cruz Biotechology). 
 
2.7 Flow cytometry analysis   
FACS analysis was performed to the leukocytes following their separation by percoll. After lysis 
of red blood cells, leukocytes were resuspended in PBS following by labelling with fluorescence-
conjugated antibodies (Ly6G (1A8), Ly6C (HK1.4), Gr-1 (RB6-8C5) and CD11b (M1/70) (all from 
Biolegend or R&D systems) and analyzed using BD LSR Fortessa (BD Biosciences). Data analysis 
was performed using FlowJo software.  
2.8 Measurement of the cytokines 
Splenocytes isolated from the spleen of healthy mice were seeded to 96 well plate at the density 
of (6 × 105) per well that had been coated or not with anti-CD3e antibodies (BioLegend).Cells 
were resuspended in complete RPMI (10% FBS, 0.1% β-mercaptoethanol and CD28, 0.5 µg/ml, 
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clone 37.51, Biolegend). For non-activated T cells, cells were cultured in complete RPMI (10 % 
FBS) without CD3 or CD28 antibodies. In case of Concanavalin A (ConA), PMA+Ionomycin and IL2 
activated T cells, T cells were cultured in RPMI (10 % FBS) + (ConA) at the final concentration of 
(0.5 μg/ ml), PMA (30ng/ml)/Ionomycin (80ng/ml) or IL-2 (1000 IU/ml) .Cell supernatant was 
collected after 1 or 4 days. Cytokines concentration was measured using standard sandwich ELISA 
technique. In brief, antibodies against IL-6, IL-10, IFNγ and GM-CSF were used to coat a 96-well 
flat-bottom ELISA plate. Following washing, both activated and non-activated T cells media were 
incubated in the wells, each sample in duplicate. Following by the incubation of Biotin labelled 
antibodies and HRP-conjugated streptavidin antibodies .wells were washed with 0.005% Tween-
20 PBS following the incubation of each antibody. Color change was detected at wavelength 
450nm following the addition of HRP substrate, o-phenylenediamine dihydrochloride (OPD, 
Sigma) to each well. All of the antibodies were purchased from BD Biosciences and BioLegend. 
Data analysis was performed using SoftMax Pro microplate data software. 
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3 RESULTS 
Although aginase-1 is believed to be an important enzyme used by myeloid derived suppressor 
cells to inhibit T cell responses, the mechanisms that control arginase-1 expression has been 
subjected to major debate and research. One study using 3LL tumor model cells showed that 
arginase-1 expression in tumor infiltrating MDSC is independent of T cell cytokines but requires 
tumor released factors[65]. A second study using C26 colon carcinoma tumor model attributed 
arginase-1 expression in blood MDSC to IFNᵧ signaling [66]while a third study proved that IFNᵧ 
does not control MDSC suppressive function and targeting of IFNᵧ as a potential therapy will not 
limit MDSC number[67]. The variability of these results suggests that, MDSC formed under 
different tumor conditions or isolated from different tissues, might be controlled differently. 
Understanding this mechanism will help to rescue of T cell responses as well as to understand 
the interplay between MDSC and T cells. In this study we hypothesized that arginase-1 expression 
in bone marrow derived MDSC requires the exposure to T cells that activated through ligation of 
CD3 and is independent of tumor released factors. 
3.1      Bone marrow-derived MDSC from tumor bearing mice suppressed T cell proliferation  
We had previously shown that bone marrow-derived Ly6C+ monocytes, both in bone marrow and 
the peripheral blood of C57BL6 mice, are natural M-MDSC, and display potent inhibition in CD3 
and CD28 ligation-induced T cell proliferation. In addition, tumor conditions induced an extensive 
expansion in bone marrow of low-density granulocytes (Ly6G+), which displayed characteristics 
of G-MDSC and as well potently inhibited T-cell proliferation. Different from M-MDSC, which are 
present constitutively, G-MDSC appear only under pathogenic conditions such as tumor. Using 
Percoll density gradients, M-MDSC and G-MDSC (both in band III) can be separated from mature 
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granulocytes, especially mature neutrophils (PMN), which displayed high cell density (band IV) 
and non-myeloid cells in bone marrow (band I-II) (Fig. 3.1A).    
Because mice MDSCs express both CD11b and Gr-1 protein, flow cytometry analysis using both 
CD11b and Gr-1 antibodies was used to identify cell types from bone marrow of both B16 bearing 
mice and control mice (healthy) following the separation by percoll. Flow cytometry analysis 
results showed that Both band III and IV from B16 bearing mice contain CD11b+Gr-1+ leukocytes 
and then further gating using Ly6G and Ly6C antibodies in fraction III show that band III contains 
immature myeloid cells that have the same phenotype of M-MDSC or G-MDSC while fraction IV 
contains about 98 % mature granulocytes (Fig. 3.1A). 
  Tumor-induced myeloid derived suppressive cells have been strongly correlated with the  
inhibition of T cell proliferation in different tumor models[2, 68].To confirm that fraction III  
formed in mice engrafted with B16 melanoma (s. c.) are immunosuppressive, fraction III 
separated cells were co-cultured with total mice splenocytes from healthy  C57BL6 mice , 
labelled with CFSE and  activated by incubating with CD3 and CD28 antibodies. As expected, CD4 
and CD8 T-cell proliferation was potently inhibited while fraction IV displayed no inhibition 
(Fig.3.1B). In addition, the co-culture of either purified Ly6G+ granulocytic cells or Ly6Chigh 
monocytic cells from fraction III with CD3/CD28 activated T cells showed inhibition of T-cell 
proliferation. Same fraction III from tumor bearing mice, inhibited Con.A, PMA or IL-2 induced T-
cell proliferation (Fig.3.1D, E). These results were also repeated using different tumor models as 
B16 melanoma, MC38 colon carcinoma and EL4 lymphoma (Fig.3.1C).These results suggest that 
these cells resemble MDSC phenotypically and functionally. 
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Figure 3-1 Bone marrow-derived MDSC from tumor bearing mice suppress T cell 
proliferation. 
A) BM collected from tumor-bearing mice were added to percoll density gradients in 15 ml tube. 
After centrifugation the cells separated into four fractions (I, II, III and IV) and MDSC present in 
fraction III followed by FACS analyses for cells in fraction III and IV using LY6Chigh and LY6G+ 
antibodies. C) Testing of MDSC suppressive activity. Cells from fraction III or IV were co-
cultured with splenocytes that activated by anti CD3/CD28 antibodies. After 4 days cells were 
stained for CD4 and CD8 T cells and cell proliferation was determined by FACS by the evaluation 
of CFSE signal. MDSC were added to splenocytes at the ratio of 1:3. Ctr is only T cells without 
any leukocytes. D, E) ConA, IL-2 and PMA activated T cells inhibited by Cells from Fraction III. 
Cells from Fraction III were co-cultured with T cells in RPMI (10 % FBS+ 0.2ug/mL ConA, PMA 
20ng/mL / Ionomycin 60ng/mL or IL-2 500 IU/mL followed by FACS analysis of T cell 
proliferation. Percentage of Ly6Chigh monocytes and Ly6G+ granulocytes in fractions III and IV 
were calculated as a percent of total BM cells.  Data are presented as mean ± SEM (n=3). ***, p 
≤ 0.001.  
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3.2      Tumor bone marrow MDSC express arginase-1 upon exposure to TCR-activated T 
cells 
Since arginase-1 is believed to be a major feature of MDSC suppressive activity, we tested 
arginase-1 expression in MDSC isolated by percoll using western blotting analysis. Although 
MDSC isolated from tumor bearing mice, profoundly inhibited T-cell proliferation, 
surprisingly, no arginase-1 expression was detected in MDSC following their isolation from 
the bone marrow. Interestingly, the incubation of MDSC from tumor bearing mice with 
CD3/CD28 activated T cells induced arginase-1 expression. As shown in figure 3.2A, the 
incubation of MDSC with CD3/CD28 activated splenocytes but not non-activated splenocytes, 
induced arginase-1 expression.  
Since splenocytes consists of different cell types such as T cells, B cells, macrophages and 
dendritic cells, we purified T-cells using CD4 and CD8 positive selection that affinity isolated 
T cells (> 97% purity). Incubation of MDSC with only CD3/CD28 activated T cells induced 
arginase-1 expression while the incubation with CD3/CD28 activated splenocytes (depleted T 
cells) failed to induce arginase-1 expression). As shown in Fig.3. 2B, MDSC co-cultured with 
purified T cells in the presence of CD3/CD28 ligation were induced to express arginase-1. 
Depletion of T cells from splenocytes in the co-culture, or removal of antibodies for TCR 
ligation, failed to induce arginase-1 expression in MDSC.   
We next tested weather Ly6Chigh monocytes (M-MDSC) and Ly6G+ granulocytes (G-MDSC) 
have the same potential to express arginase-1. Our results show that, both M-MDSC and G-
MDSC isolated from the bone marrow of tumor bearing mice tend to express arginase-1 only 
after the exposure to CD3/CD28 activated T cells.  As shown in Figure 2C, the co-culture of 
either M-MDSC or G-MDSC with CD3/CD28 activated T cells successfully induced arginase-
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1 expression that was not detected following the isolation from tumor-bearing mice. Consistent 
with that, no arginase-1 expression was detected in the mature granulocytes from tumor 
bearing mice before or after the exposure to CD3/CD28 activated T cells (Fig.3. 2C). Arginase-
1 expression was detected after (18 – 24 hrs.) but not shorter time (3 or 6 hrs.) (Fig.3. 2D). 
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Figure 3-2 Bone marrow-derived MDSC express no arginase but until after exposure 
to activated T cells. 
A) Western blotting to detect arginase-1 expression in MDSC before (-) or after (+) co-culture 
with activated or non-activated splenocytes after incubating for overnight (18 hrs.). B) Arginase-
1 expression in MDSC requires activated T cells. Western blotting of arginase-1 expression before 
or after co-culture with activated splenocytes (SP), splenocytes without T cells or purified T cells. 
C) Fraction III Ly6G+ granulocytes and Ly6Chigh monocytes, and fraction IV mature PMN isolated 
from  B16 melanoma-bearing mice were tested for arginase expression before (-) and after (+) 
addition into the CD3/CD28 activated T cells for 18 h.  D) Time course for arginase-1 expression 
by MDSC after co-culture with CD3/CD28 activated T cells. 
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3.3 Arginase-1 expression by bone marrow derived MDSC is independent of direct contact 
with T cells. 
We next investigated whether the induction of arginase-1 expression in bone marrow derived 
MDSC that primarily triggered by CD3/CD28 activated T cells requires direct contact with T cells. 
We found that arginase-1 expression is induced in bone marrow derived MDSC by a mechanism 
that does not necessarily require contact between MDSC and CD3/CD28 activated T cells. As 
shown in figure (3.3.A), the culture of MDSC isolated from bone marrow of tumor-bearing mice 
in culture supernatant collected from CD3/CD28 activated total splenocytes or purified CD4 and 
CD8 T cells successfully induced arginase-1 expression while the incubation in culture supernatant 
collected from non-activated T cells, B16 tumor cells failed to induce arginase-1 expression. 
Furthermore, incubation of MDSC in culture supernatant isolated from either CD3/CD28 activated 
CD4 or CD8 T cells induced arginase-1 expression (Fig. 3.3.B).In addition, both M-MDSC and 
G-MDSC expressed arginase-1 only after being treated with CD3/CD28 activated T cells 
supernatant which is similar to the result that we got from the co-culture system (Fig.3.3C). This 
result suggested that, bone marrow derived MDSC from tumor bearing mice do not constitutively 
express arginase-1 but instead arginase-1 expression induced once MDSC was exposed to 
activated T cell environment.  
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3.4 Arginase-1 induction in BM derived MDSC by activated T cells requires ligation of 
TCR co-receptor (CD3). 
Since different activators such as Concanavalin A (ConA), PMA plus Ionomycin and IL-2 have 
the ability to induce T-cell proliferation, we sought to determine whether T-cells activated by 
ConA, PMA plus Ionomycin or IL-2 induce arginase-1 expression in MDSC. Although ConA, 
PMA plus Ionomycin or IL-2 successfully activated T cell proliferation, interestingly, only T cells 
activated via ligation of CD3 induced arginase-1 expression. As shown in figure (3.4A,B), 
incubation of MDSC with culture supernatant isolated from T cells that had been activated by IL-
2, ConA or PMA plus Ionomycin failed to induce arginase-1 expression but only MDSC that 
incubated with cell culture supernatant isolated from CD3/CD28 activated cells successfully 
induced arginase-1.This result suggested that T cells activation through ligation of CD3 but not 
other ways of activation can induce arginase-1 enzyme expression in myeloid derived suppressor 
cells. 
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Figure 3-3 Arginase-1 expression by BM derived MDSC is independent of direct contact with T 
cells. 
 
A) Arginase-1 expression in MDSC (FIII) isolated from tumor bearing mice after the treatment 
using 50% CD3/CD28 activated splenocytes, T cells or B16 cells supernatant. B) Induction of 
arginase-1 expression by either CD3/CD28 CD4 or CD8 activated T cells supernatant. C) 
Arginase-1 expression detection in fraction III Ly6G+ granulocytes and Ly6Chigh monocytes. 
Fraction III Ly6G+ granulocytes or Ly6Chigh    were tested for arginase-1 expression after overnight 
treatment with supernatant collected from T cells after overnight activation with CD3/CD28 
antibodies.B-actin was used as a loading control. 
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Figure 3-4 Arginase-1 induction in BM derived MDSC by activated T cells requires 
ligation of TCR co-receptor (CD3). 
 
A) T cell proliferation after incubating of T cells with PMA (30ng/ml)/Ionomycin (80 ng/ml), 
ConA (0.5 μg/ ml) or IL-2 (1000 IU/ml). B) Arginase-1 expression in F III (MDSC) after treatment 
with supernatant collected from activated T cells showed in (A).  
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3.5  Healthy Ly6Chigh monocytes but not Ly6G+ granulocytes express arginase-1 upon the 
exposure to CD3/CD28 activated T cells. 
We had shown that Ly6Chigh monocytes but not Ly6G+ granulocytes isolated from the bone 
marrow of healthy C57BL6 mice, inhibited T cell proliferation in a similar manner to their 
counterpart isolated from tumor bearing mice (fig. 3-5.A).We next sought to determine whether 
Ly6Chigh monocytes isolated from bone marrow of healthy mice express arginase-1 after being 
exposed to CD3/CD28 activated T cell or its supernatant. As shown in figure 3-5B, Ly6Chigh 
monocytes but not Ly6G+ granulocytes from healthy mice expressed arginase-1 after co-culture 
with CD3/CD28 activated T cells. Furthermore, treatment with supernatant isolated from T cells 
activated by CD3/CD28 antibodies, induced arginase-1 expression while no arginase-1 expression 
was detected in mature granulocytes before or after treatment with similar supernatant. This 
suggested that not only MDSC that formed under tumor or disease conditions have the potential 
to express arginase-1 but also Ly6Chigh monocytes can express arginase-1 after being exposed to 
CD3/CD28 activated T cells and can be considered as natural MDSCs. 
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Figure 3-5 Healthy Ly6Chigh monocytes but not Ly6G+ granulocytes express arginase-1 
only after the exposure to CD3/CD28 activated T cells. 
A) Evaluation of LY6Chigh suppressive activity by inhibiting T cell proliferation. Splenocytes were 
labelled with CFSE and incubated in plates immobilized with anti-CD3 and in the presence of 
soluble anti-CD28 antibodies, in presence of myeloid cells isolated from healthy mice or without 
any myeloid cells (ctl.) for 4 days before FACS analyses. The ratio of splenocytes: myeloid cells 
was 3:1. B) Arginase-1 detection in LY6Chigh or LY6G+ cells from band III isolated by percoll from 
BM of healthy mice before and after co-culture with CD3/CD28 activated T cells. Data are 
presented as mean ± SEM (n=3). ***, p ≤ 0.001.  
 
 
CD4 CD8 
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4 DISCUSSION 
MDSC are one of the suppressive cell types found in the tumor microenvironment  associated 
with suppression of T cell responses and enhancing tumor progression[69]. Blocking MDSC 
activity had been shown to have a negative effect on tumor progression[70]. Suppression of T 
cell responses by MDSC had been shown to be associated with arginase-1 enzyme[71]. 
However, We found that arginase-1 enzyme is not constitutively expressed in bone marrow 
derived MDSC isolated from tumor-bearing mice, instead required to be induced .In our study 
we showed that T cells activated via the ligation of CD3 induced arginase-1 expression in BM 
derived MDSC. Although many reports had shown that MDSC inhibition of T-cell 
proliferation require direct contact between MDSC and T cells [21, 72], our results showed 
that direct contact between MDSC and activated T cells is not required for arginase-1 enzyme 
induction in bone marrow derived MDSC. Supernatant collected from CD3/CD28 activated T 
cells, induced arginase-1 expression suggesting the presence of diffusible factors that are 
released after T cell activation leading to the induction of arginase-1 expression in bone 
marrow derived MDSC. The culture of bone marrow derived MDSC with resting T cells failed 
to induce arginase-1 enzyme expression. This result is consistent with previous results that 
showed that arginase-1 suppressive activity required the presence of activated T cells[72]. We 
also showed that both monocytic MDSC (M-MDSC) and granulocytic MDSC (G-MDSC) 
expressed arginase-1 after being treated with CD3/CD28 activated T cell supernatant.  
Even though tumor released factors had been shown to induce arginase -1 expression in tumor 
infiltrating myeloid suppressor cells [65], we did not see any arginase-1 expression in bone 
marrow derived MDSC after treatment with supernatant collected from B16 cells. But instead, 
our data demonstrated that soluble factors released from CD3/CD28 activated T cells induced 
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arginase-1 in bone marrow derived MDSC in vitro. Thus, we hypothesized that bone marrow 
derived MDSC express no arginase-1, but once they enter the tumor microenvironment and 
encounter activated T cells, MDSC will express arginase-1 as a result of CD3 activated T cell 
released factors.  
Interestingly, our data showed that arginase-1 expression required CD3/CD28 activated T cells 
but not other ways of activation. In our study, the co-culture of MDSC with ConA, IL-2 or 
PMA activated T cells potently inhibited T-cell proliferation. However, we failed to detect 
arginase-1 expression in MDSC after the co-culture with IL-2, ConA or PMA activated T cells. 
This result suggested the presence of a different mechanism of suppression rather than 
arginase-1 enzyme activity which is believed to be an NO-dependent mechanism[72]. This was 
confirmed by the use of an iNOS inhibitor (l-NMMA) which profoundly rescued T-cell 
proliferation[72]. Furthermore, neither IL-2, ConA nor PMA activated T cells culture 
supernatant induced arginase-1 expression in bone marrow derived MDSC suggesting a 
difference in soluble factors released from activated T cells using different activators. 
We and others had shown that LY6Chigh monocytes isolated from healthy mice suppressed T-
cell proliferation[73]. Our results demonstrated that in a similar manner to their counterparts 
from tumor-bearing mice, LY6Chigh monocytes from healthy mice expressed arginase-1 only 
after the exposure to CD3/CD28 activated T cells. Indeed, this observation might provide a 
mechanism to treat autoimmune diseases. 
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